Equities Analysts Set Expectations for Quest Diagnostics Inc’s FY2018 Earnings (DGX)
Quest Diagnostics Inc (NYSE:DGX) – Analysts at KeyCorp lowered their FY2018 EPS estimates for Quest Diagnostics in a report released on Wednesday, December 5th. KeyCorp analyst D. Hooker now expects that the medical research company will post earnings of $6.36 per share for the year, down from their previous estimate of $6.54. KeyCorp also issued estimates for Quest Diagnostics’ Q4 2018 earnings at $1.40 EPS, Q1 2019 earnings at $1.68 EPS, FY2019 earnings at $6.70 EPS and FY2020 earnings at $7.04 EPS.
Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, October 23rd. The medical research company reported $1.68 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.68. Quest Diagnostics had a return on equity of 15.71% and a net margin of 11.30%. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter in the previous year, the firm posted $1.38 EPS. The firm’s quarterly revenue was up 1.8% on a year-over-year basis.
NYSE DGX opened at $88.83 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.09 and a current ratio of 1.15. Quest Diagnostics has a 12-month low of $85.56 and a 12-month high of $116.49. The company has a market cap of $12.21 billion, a price-to-earnings ratio of 16.45, a price-to-earnings-growth ratio of 1.87 and a beta of 0.89.
A number of large investors have recently made changes to their positions in DGX. Dupont Capital Management Corp grew its holdings in Quest Diagnostics by 64.4% during the 2nd quarter. Dupont Capital Management Corp now owns 1,202 shares of the medical research company’s stock valued at $132,000 after buying an additional 471 shares during the last quarter. Aperio Group LLC raised its position in shares of Quest Diagnostics by 2.1% in the 2nd quarter. Aperio Group LLC now owns 93,127 shares of the medical research company’s stock worth $10,238,000 after buying an additional 1,914 shares during the period. TD Asset Management Inc. raised its position in shares of Quest Diagnostics by 8.9% in the 2nd quarter. TD Asset Management Inc. now owns 42,508 shares of the medical research company’s stock worth $4,673,000 after buying an additional 3,487 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Quest Diagnostics by 20.9% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 51,955 shares of the medical research company’s stock worth $5,712,000 after buying an additional 8,972 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Quest Diagnostics by 3.9% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 428,400 shares of the medical research company’s stock worth $47,098,000 after buying an additional 16,069 shares during the period. Hedge funds and other institutional investors own 86.26% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 30th. Shareholders of record on Tuesday, January 15th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date is Monday, January 14th. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.50. Quest Diagnostics’s dividend payout ratio is 37.04%.
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.
Featured Story: What is a Roth IRA?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.